ARCT250117P7500
- 0.00
- 0.000.00%
Arcturus Therapeutics Newsroom
Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency; Phase 2 Interim Data For Both MRNA Therapeutic Programs On Track For First Half Of 2025
Express News | Arcturus Therapeutics Holdings Inc -Phase 2 Interim Data for Both Mrna Therapeutic Programs on Track for First Half of 2025
Express News | Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT) and Madrigal Pharmaceuticals (MDGL)
Arcturus Therapeutics Price Target Maintained With a $63.00/Share by HC Wainwright & Co.
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight
Arcturus Therapeutics Analyst Ratings
This Arcturus Therapeutics Holdings Insider Reduced Their Stake By 18%
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers
Positive Outlook for Arcturus Therapeutics Driven by Innovative Vaccine Kostaive
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $74
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
Express News | Meiji Seika Pharma Announces Investment in Arcalis, Inc.
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Arcturus Therapeutics: Overcoming Challenges and Poised for European Expansion
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate
Arcturus Therapeutics Receives FDA Clearance to Begin H5N1 Vaccine Trial
Express News | Arcturus Therapeutics Holdings Inc - Study to Enroll Approximately 200 Healthy Adults in U.S.